Apollo Health Ventures

What Apollo Health Ventures does

Apollo Health Ventures is a transatlantic early-stage venture capital firm founded in 2017 in Hamburg, Germany, that co-founds and invests in biotechnology companies developing therapeutics and data-driven interventions targeting age-related diseases and the biology of aging itself. The firm operates through two complementary approaches: a Venture Lab that partners with leading research institutes and scientists to convert untapped technologies into new companies (acquiring founder shares at nominal value), and selective investing in best-in-class external seed and Series A deals. Capital is deployed from Apollo Health Ventures Fund II, which closed at $180 million in December 2021, and the firm explicitly excludes medical device companies while including data analytics businesses focused on the causes of age-related disease.

The portfolio spans 13+ named companies including HAYA Therapeutics, Aeovian Pharmaceuticals, Auron Therapeutics, Cognito Therapeutics, Booster Therapeutics, Cleara Biotech, Ochre Bio, Scripta Therapeutics, Nula Therapeutics, and Bionyra Pharma, collectively raising capital in over 30 financing rounds with combined valuations exceeding $1 billion. The business model is standard asset management: management fees on committed capital plus carried interest on exits, with distribution limited to eligible investors under KAGB and EuVECA regulations. Apollo Health Ventures generates revenue by deploying scientific and operational expertise (interim CEO support, R&D guidance, clinical trial strategy) alongside capital, and operates from offices in Berlin, Boston, and Luxembourg to source deals across Europe and North America.

Name

Apollo Health Ventures

Legal name

Apollo Ventures Holding GmbH

Website

https://apollo.vc

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Apollo Health Ventures is a transatlantic venture capital firm founded in 2017 that co-founds and invests in seed and Series A biotechnology companies targeting age-related diseases and the biology of aging, deploying capital from its $180 million Fund II across Europe and the US.

Ownership category

akta.pro rank

Product category

Venture Capital (Life Sciences)

NAICS

Portfolio Management and Investment Advice (523940), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

Keywords

• Venture capital funding
• Early-stage biotech
• Longevity therapeutics
• Age-related disease
• Venture creation

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others, Technology or R&D

Revenue model

1. Management Fees and Carried Interest: Apollo Health Ventures generates revenue through management fees charged on its managed funds and carried interest (performance fees) on investment returns. Fund II closed at $180 million, with the firm investing in both venture creation and external dealflow companies targeting age-related diseases and aging itself.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Apollo Health Ventures is a transatlantic early-stage venture capital firm that co-founds and invests in transformative biotechnology and health tech companies targeting age-related diseases and aging itself. The firm operates through two core approaches: (1) active venture creation via its Venture Lab, which partners with scientific experts to convert untapped technologies into new companies and acquires founder shares at nominal value; and (2) early-stage investment in best-in-class external companies at seed and Series A stages, with Fund II sized at $180 million.

Product overview

Apollo Health Ventures is a transatlantic venture capital firm that specializes in co-founding and investing in transformative healthcare and biotechnology companies targeting age-related diseases and aging itself. The firm operates through two core investment approaches: (1) Active Venture Creation via its Venture Lab, where it partners with scientific experts to turn untapped technologies into transformational companies by acquiring founder shares at nominal value; and (2) Investing in best-in-class external companies at early stages based on breakthrough science. Apollo does not sell products or services to end customers; rather, it builds and supports portfolio companies including Aeovian Pharmaceuticals, Auron Therapeutics, Bloom Science, Booster Therapeutics, Cleara Biotech, Focal Biosciences, Galilei Biosciences, HAYA Therapeutics, Ochre Bio, Refoxy Pharmaceuticals, Samsara Therapeutics, ThymoFox, and YEARS, among others.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Lab (Venture Creation) A structured venture creation service that partners with leading research institutes and scientists in the aging sector to convert untapped technologies into transformational biotech companies, targeting early-stage dealflow with unique upside for investors.
• Apollo Health Ventures Fund II A $180 million venture capital fund that invests in biotech and health tech companies developing interventions targeting age-related diseases and underlying causes of aging, supporting both internal venture creation and external early-stage dealflow at seed and Series A.
• Early-Stage Portfolio Investment Investment in best-in-class early-stage biotech and health tech companies based on breakthrough science, providing capital, talent recruitment, R&D guidance, clinical trial strategy, and follow-on investment support across Seed and Series A rounds.

Quantifiable outcome

• Fund II closed at $180 million (€157.5 million)
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered minor.

• TrueLab BiopharmaceuticalminorOthers · 22 June 2026Apollo portfolio company Bionyra Pharma acquired exclusive global rights outside Greater China to two TL1A-targeting assets (BYN-002 and BYN-003) from TrueLab Biopharmaceuticals. BYN-002 is currently in Phase 1 and BYN-003 entered the clinic in April.
• NovaRock BiotherapeuticsminorOthers · 22 June 2026Apollo portfolio company Bionyra Pharma acquired exclusive global rights outside Greater China to BYN-001 from NovaRock Biotherapeutics. The company holds exclusive global rights to three immunology assets from NovaRock and TrueLab.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Others

• SR One (GSK): Corporate venture arm of GSK, previously led by Apollo advisor Dr. Jens Eckstein. Indirect peer with strategic pharma-backed biotech investment focus and similar therapeutic areas.

Emerging players

• Andreessen Horowitz (a16z Bio): Major US venture firm building a dedicated bio/health fund with longevity investments. Recent entrant into the aging biotech space, representing a more capitalized competitor for deal flow.

Direct peers

• Longevity Vision Holding: Direct peer focused exclusively on longevity and anti-aging investments with similar early-stage biotech thesis. Both firms invest in breakthrough science targeting aging biology and have comparable fund sizes and transatlantic scope.
• LongeVC: Direct peer with longevity-focused investment thesis spanning early-stage biotech and healthspan companies. Comparable in check size, stage focus (Seed/Series A), and exclusive aging biology orientation.
• Kizoo Technology Capital: Direct peer and fellow German-based longevity VC. Both firms pursue venture creation in the aging biology space and share the conviction that treating aging as a root cause is the highest-impact healthcare investment thesis.

Broad incumbents

• Sofinnova Partners: Major European life sciences VC frequently co-investing with Apollo (e.g., Aeovian, Bionyra). Comparable biotech investment stage and structure, though Sofinnova has broader therapeutic breadth across multiple indications.
• Forbion: Established European life sciences VC with broader therapeutic focus. Apollo recently hired Forbion principal Antoine Boulanger as Partner, indicating direct talent and thematic overlap in biotech investment.
• Wellington Partners: European life sciences VC where Apollo Partner Dr. Marianne Mertens previously worked as Principal. Overlapping biotech investment thesis and similar stage preferences.
• Jeito Capital: European biotech VC co-leading rounds with Apollo in portfolio companies (e.g., Bionyra $165M Series A). Similar stage focus and biotech thesis, with comparable transatlantic reach.
• Khosla Ventures: US venture firm with significant longevity/anti-aging biotech deployment. Direct competitor for the same biotech deals at comparable stages, with much larger fund vehicles.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/apollohealthvc
• LinkedInlinkedin.com/company/ahv

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments23 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apollo Health Ventures